REGENXBIO Inc. - stock earnings
RGNX Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 1, 2024 BeforeMarket | - / -1.2800000000 | - | - / 23.5 million | - |
RGNX Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -62.9 million USD | 22.2 million USD |
| 2023Q3 | -61.9 million USD | 28.9 million USD |
| 2023Q2 | -72.1 million USD | 20.0 million USD |
| 2023Q1 | -70.0 million USD | 19.1 million USD |
| 2022Q4 | -59.9 million USD | 31.3 million USD |
| 2022Q3 | -79.9 million USD | 26.5 million USD |
| 2022Q2 | -73.8 million USD | 32.6 million USD |
| 2022Q1 | -76.7 million USD | 22.2 million USD |
| 2021Q4 | 294.0 million USD | 398.7 million USD |
| 2021Q3 | -58.4 million USD | 30.8 million USD |
| 2021Q2 | -57.6 million USD | 22.0 million USD |
| 2021Q1 | -50.1 million USD | 18.9 million USD |
| 2020Q4 | -46.2 million USD | 21.4 million USD |
| 2020Q3 | 8.8 million USD | 98.9 million USD |
| 2020Q2 | -33.8 million USD | 16.6 million USD |
| 2020Q1 | -40.0 million USD | 17.6 million USD |
| 2019Q4 | -26.5 million USD | 11.8 million USD |
| 2019Q3 | -34.6 million USD | 14.7 million USD |
| 2019Q2 | -1.5 million USD | 7.9 million USD |
| 2019Q1 | -32.2 million USD | 884000 USD |
| 2018Q4 | 4.3 million USD | 40.8 million USD |
| 2018Q3 | -19.2 million USD | 5.3 million USD |
| 2018Q2 | 10.6 million USD | 40.0 million USD |
| 2018Q1 | 104.2 million USD | 132.4 million USD |
| 2017Q4 | -16.0 million USD | 2.0 million USD |
| 2017Q3 | -20.7 million USD | 1.3 million USD |
| 2017Q2 | -14.5 million USD | 6.6 million USD |
| 2017Q1 | -22.0 million USD | 455000 USD |
| 2016Q4 | -19.6 million USD | 1.7 million USD |
| 2016Q3 | -18.2 million USD | 125000 USD |
| 2016Q2 | -14.4 million USD | 2.4 million USD |
| 2016Q1 | -10.8 million USD | 393000 USD |
| 2015Q4 | -5.2 million USD | 4.4 million USD |
| 2015Q3 | -7.3 million USD | 1.1 million USD |
| 2015Q2 | -6.3 million USD | 1.4 million USD |
| 2015Q1 | -4.0 million USD | 644000 USD |
| 2014Q4 | -2.3 million USD | 1.1 million USD |
| 2014Q3 | -1.8 million USD | 483000 USD |
| 2014Q2 | 126000 USD | 4.5 million USD |
| 2013Q4 | ? USD | 6.1 million USD |
RGNX Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -263.5 million USD | 90.2 million USD |
| 2022 | -280.3 million USD | 112.7 million USD |
| 2021 | 127.8 million USD | 470.3 million USD |
| 2020 | -111.3 million USD | 154.6 million USD |
| 2019 | -94.7 million USD | 35.2 million USD |
| 2018 | 99.9 million USD | 218.5 million USD |
| 2017 | -73.2 million USD | 10.4 million USD |
| 2016 | -63.0 million USD | 4.6 million USD |
| 2015 | -22.8 million USD | 7.6 million USD |
| 2014 | -4.0 million USD | 6.1 million USD |
| 2013 | -5.4 million USD | 6.1 million USD |
RGNX
Price: $16.19
52 week price:
Earnings Per Share: -6.02 USD
P/E Ratio: -2.43
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 295200
Ebitda: -20.6 millionMarket Capitalization: 939.2 million